BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24884612)

  • 1. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth.
    Liu N; He QM; Chen JW; Li YQ; Xu YF; Ren XY; Sun Y; Mai HQ; Shao JY; Jia WH; Kang TB; Zeng MS; Ma J
    Mol Cancer; 2014 May; 13():111. PubMed ID: 24884612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
    Khanna A; Böckelman C; Hemmes A; Junttila MR; Wiksten JP; Lundin M; Junnila S; Murphy DJ; Evan GI; Haglund C; Westermarck J; Ristimäki A
    J Natl Cancer Inst; 2009 Jun; 101(11):793-805. PubMed ID: 19470954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer.
    Chen W; Liang JL; Zhou K; Zeng QL; Ye JW; Huang MJ
    Cell Commun Signal; 2020 Apr; 18(1):67. PubMed ID: 32321509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.
    Guo Z; Liu D; Su Z
    Tumour Biol; 2015 Jun; 36(6):4777-83. PubMed ID: 25636449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression.
    Liu ZH; Hu JL; Liang JZ; Zhou AJ; Li MZ; Yan SM; Zhang X; Gao S; Chen L; Zhong Q; Zeng MS
    Cell Death Dis; 2015 Oct; 6(10):e1920. PubMed ID: 26469968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma.
    Xue Y; Wu G; Wang X; Zou X; Zhang G; Xiao R; Yuan Y; Long D; Yang J; Wu Y; Xu H; Liu F; Liu M
    Med Oncol; 2013 Mar; 30(1):406. PubMed ID: 23275123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of Talin-1 is associated with poor prognosis in patients with nasopharyngeal carcinoma.
    Xu YF; Ren XY; Li YQ; He QM; Tang XR; Sun Y; Shao JY; Jia WH; Kang TB; Zeng MS; Liu N; Ma J
    BMC Cancer; 2015 Apr; 15():332. PubMed ID: 25925041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis.
    Dong QZ; Wang Y; Dong XJ; Li ZX; Tang ZP; Cui QZ; Wang EH
    Ann Surg Oncol; 2011 Mar; 18(3):857-65. PubMed ID: 20842459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CIP2A mediates prostate cancer progression via the c-MYC signaling pathway.
    Guo Z; Liu D; Su Z
    Tumour Biol; 2015 May; 36(5):3583-9. PubMed ID: 25560487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression.
    Wiegering A; Pfann C; Uthe FW; Otto C; Rycak L; Mäder U; Gasser M; Waaga-Gasser AM; Eilers M; Germer CT
    PLoS One; 2013; 8(10):e75292. PubMed ID: 24098375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-451 inhibits cell growth and invasion by targeting MIF and is associated with survival in nasopharyngeal carcinoma.
    Liu N; Jiang N; Guo R; Jiang W; He QM; Xu YF; Li YQ; Tang LL; Mao YP; Sun Y; Ma J
    Mol Cancer; 2013 Oct; 12(1):123. PubMed ID: 24138931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIPE3 hypermethylation correlates with worse prognosis and promotes tumor progression in nasopharyngeal carcinoma.
    Ren XY; Wen X; Li YQ; Zhang J; He QM; Yang XJ; Tang XR; Wang YQ; Zhang PP; Chen XZ; Cheng B; Ma J; Liu N
    J Exp Clin Cancer Res; 2018 Sep; 37(1):227. PubMed ID: 30217224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CIP2A is associated with human breast cancer aggressivity.
    Côme C; Laine A; Chanrion M; Edgren H; Mattila E; Liu X; Jonkers J; Ivaska J; Isola J; Darbon JM; Kallioniemi O; Thézenas S; Westermarck J
    Clin Cancer Res; 2009 Aug; 15(16):5092-100. PubMed ID: 19671842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CIP2A overexpression is associated with c-Myc expression in colorectal cancer.
    Böckelman C; Koskensalo S; Hagström J; Lundin M; Ristimäki A; Haglund C
    Cancer Biol Ther; 2012 Mar; 13(5):289-95. PubMed ID: 22310977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive CHK1 Expression Drives a pSTAT3-CIP2A Circuit that Promotes Glioblastoma Cell Survival and Growth.
    Khanna A; Thoms JAI; Stringer BW; Chung SA; Ensbey KS; Jue TR; Jahan Z; Subramanian S; Anande G; Shen H; Unnikrishnan A; McDonald KL; Day BW; Pimanda JE
    Mol Cancer Res; 2020 May; 18(5):709-722. PubMed ID: 32079743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIMELESS confers cisplatin resistance in nasopharyngeal carcinoma by activating the Wnt/β-catenin signaling pathway and promoting the epithelial mesenchymal transition.
    Liu SL; Lin HX; Lin CY; Sun XQ; Ye LP; Qiu F; Wen W; Hua X; Wu XQ; Li J; Song LB; Guo L
    Cancer Lett; 2017 Aug; 402():117-130. PubMed ID: 28583847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
    Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
    Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CIP2A is a predictor of poor prognosis in colon cancer.
    Teng HW; Yang SH; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Chen PC; Lan YT; Lin CC; Hsu YN; Wang HW; Chen KF
    J Gastrointest Surg; 2012 May; 16(5):1037-47. PubMed ID: 22328001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion.
    Zhai M; Cong L; Han Y; Tu G
    Tumour Biol; 2014 Feb; 35(2):1123-8. PubMed ID: 24014087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. microRNA-342-3p targets FOXQ1 to suppress the aggressive phenotype of nasopharyngeal carcinoma cells.
    Cui Z; Zhao Y
    BMC Cancer; 2019 Jan; 19(1):104. PubMed ID: 30678643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.